Oncology biotech Tyra Biosciences files for a $100 million IPO

Tyra Biosciences, which is developing FGFR inhibitors for cancer, filed plans with the SEC to raise up to $100 million in an initial public offering, as reported in Renaissance Capital.

The company is using its proprietary SNÅP platform to generate next-generation candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options.

Its lead candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.

Tyra anticipates filing an investigational new drug application for TYRA-300 in mid-2022.